ORGO · Organogenesis Holdings Inc.
Market Cap
$191.73M
Shares
128.67M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.49
Open$1.56
Day$1.47–1.56
52W close$1.49–6.54
Avg vol 30d878K
Short int14.2M · 11.1% float · 24.0d
Short vol53%
Last earningsAug 6, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 8 wks
filed Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$457.45M
Trailing 12 months
Net income (TTM)
−$84.16M
Trailing 12 months
Revenue growth YoY
-56.7%
Year over year
Operating margin
-7.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
10.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.4%
Year over year · more shares
Price change (1Y)
-70.4%
Trailing year
Short interest
11.1%
Latest settlement · 24.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−51%
below
Price vs 50-day avg
−29%
below
RSI (14)
29
oversold
MACD trend
Positive
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−15%
trailing
6-month return
−38%
trailing
YTD return
−71%
this year
Relative strength
−56%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
+12% holders QoQ · +31 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
11.07% of float · ▲ +0.1% MoM · 24.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
135 holders — mid 3-yr range
Squeeze score
57
elevated · 0–100
Fundamentals
Revenue growth
+17%
Y/Y
Gross margin
65%
contracting
EPS growth
+1600%
Y/Y
Free cash flow
$-24.5M
Balance sheet
$37.3M
net cash
Quant / Vol
risk profile
Volatility
78%
annualized · 1-yr
Max drawdown
−77%
past year
ATR
7.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
year ending December 31, 2026
Total net revenue
Initiated
$179M – $215M
prior FY $564.17M
midpoint −65.1% Y/Y
second half 2026
Second half revenue decline year over year
Initiated
64% – 74%
Prior guidance
period ended
· from the Earnings Call filed Nov 9, 2021
Net revenue
· 12 months ended December 31, 2021
$458M – $470M
Net revenue from Advanced Wound Care products
· 12 months ended December 31, 2021
$425M – $434M
Total GAAP operating expenses
· full year 2021
27%
Net revenue from sale of PuraPly products
· 12 months ended December 31, 2021
$196M – $204M
Non-cash stock comp
· full year 2021
$3.5M
Non-cash G&A
· full year 2021
$10M
Total interest and other expenses
· full year 2021
$9.5M
Gross margins
· full year of 2021
75%
GAAP operating expenses
· full year of 2021
27%
CapEx
· full year 2021
$30M
Guided vs delivered
· last 1 settled
Net revenue
12 months ended December 31, 2021
guided $458M – $470M
$467.36M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−51%
Bearish
Price vs 50-day avg
−29%
Bearish
RSI (14)
29
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
+12% holders QoQ · +31 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
11.07% of float · ▲ +0.1% MoM · 24.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
135 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 0%
Range high $7
vs 200-day avg -51%
vs 50-day avg -29%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ORGO
this stock
Organogenesis Holdings Inc.
|
$191.73M | -71.2% | +17.0% | — | 11.1% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$58.31B | +17.1% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$44.03B | -8.9% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$43.22B | +18.8% | +4.3% | 60.8 | 3.2% |
|
HLN
Haleon plc
|
$40.41B | -9.1% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ORGO | -9.2% | -15.3% | -37.7% | -13.4% | -71.2% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -8.0% | -13.6% | -55.5% | -13.0% | -83.3% |
Key facts
CIK
1661181
CUSIP
68621F102
13F (30d)
48 filings
48 filers
Visit website
Investor relations